Sue Perera

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Meletios Α. Dimopoulos, Vânia Hungria, Atanas Radinoff et al. · The Lancet Haematology · 2023 · 124 citations

Medicine, Pharmacology, Pharmacotherapy +13

Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease

Joanne E. Brady, Marni Stott‐Miller, George Mu et al. · Clinical Therapeutics · 2018 · 54 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn’s Disease

Sue Perera, Shibing Yang, Marni Stott‐Miller et al. · Journal of health economics and outcomes research · 2018 · 23 citations · Full text

Medicine, Clinical Sciences, Pharmacoeconomics +17

Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment

Caitlin Thomas, Sikander Ailawadhi, Rakesh Popat et al. · Frontiers in Medicine · 2023 · 18 citations · Full text

Pharmacy, Pharmacotherapy, Decision Analysis +16

Clinical and Cost Burden of Primary Sjögren’s Syndrome: Descriptive Analysis Using a US Administrative Claims Database

Sue Perera, Liyuan Ma, Raj Punwaney et al. · Journal of health economics and outcomes research · 2018 · 13 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17